Island Pharmaceuticals has announced it is advancing GMP manufacturing of its antiviral, Galidesivir, to support a pivotal Marburg study under the US FDA Animal Rule pathway.

Executive Chair Dr Pete Smith said, “The support from our shareholders is deeply appreciated. Achieving a 97 per cent conversion rate is a remarkable outcome and an endorsement of our clinical development program for RC220."

Tetratherix has raised $15 million through a placement to institutional investors and announced a share purchase plan to raise up to a further $2 million from eligible shareholders.

Percheron Therapeutics and researchers at QIMR Berghofer unveiled new preclinical findings at the American Society for Clinical Oncology annual meeting suggesting that the immune checkpoint VISTA is a potential driver of treatment resistance in triple-negative breast cancer.

The three-year project will seek new ways to repair the heart and improve outcomes for people recovering from heart attacks or living with heart disease.

Chimeric Therapeutics has reported encouraging early results from its CHM CDH17 program, which were presented at the American Society of Clinical Oncology.

Cynata Therapeutics has been notified by the World Health Organization that the name Pixenstrocel has been selected as the proposed International Nonproprietary Name (INN) for its Cymerus iPSC-derived mesenchymal stem cells.

AusBiotech has announced a major change that will bring its three flagship conferences together as a single, connected week on the Gold Coast in October 2026.

BCAL Diagnostics has taken a step toward bringing its flagship blood test to the United States by signing a Validation Agreement with Sonic Healthcare USA.

Imugene has moved to bolster its board by appointing two experienced non-executive directors and launching a package of governance and remuneration reviews.

Trajan Group has updated investors that market demand for its analytical science and device products remained broadly in line with expectations during the second half of financial year 2026 and that the business continues to grow on a fixed foreign exchange basis.

Neurizon Therapeutics has announced that Regimen I of the HEALEY ALS Platform Trial will grow from 160 participants to 240, a decision the company attributed to faster-than-expected enrolment and the absence of a concurrent regimen during the recruitment window.

The licence would cover the Kingdom of Saudi Arabia, the Gulf Cooperation Council countries and key North African markets, including Egypt, Algeria and Morocco, while Recce would remain responsible for manufacture and supply.

The company said it has now developed oligonucleotides that can greatly amplify TLR8 activity compared with current best-in-class drugs in clinical development, which could in turn enhance the cancer-fighting activity of standard-of-care therapies such as chemotherapy and radiotherapy.

Imugene has released Phase 1b data that show promising activity for its off-the-shelf allogeneic CAR T therapy Azer-cel in patients with relapsed or refractory B-cell malignancies who had not previously received autologous CAR T treatment.

Percheron Therapeutics (ASX:PER) has announced that the World Health Organization has selected 'minperstobart' as the proposed international nonproprietary name for its investigational cancer therapy HMBD-002.

NeuroScientific Biopharmaceuticals has reported significant outcomes from its Special Access Program treating fistulising Crohn’s disease with the company's StemSmart mesenchymal stem cell therapy.